| scholarly article | Q13442814 |
| P50 | author | Geert Leroux-Roels | Q45380570 |
| P2093 | author name string | Adrian Cassidy | |
| Antonio Olivieri | |||
| Marc De Ridder | |||
| Sally Mossman | |||
| P2860 | cites work | Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence | Q45381659 |
| Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of hepatitis B virus | Q45404771 | ||
| Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient | Q45406775 | ||
| Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. | Q45511057 | ||
| The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. | Q45710821 | ||
| Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan | Q45768644 | ||
| Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee | Q45848619 | ||
| Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine | Q47786178 | ||
| Nucleic acid testing to detect HBV infection in blood donors. | Q50548264 | ||
| A new algorithm for deduction of hepatitis B surface antigen subtype determinants from the amino acid sequence. | Q51926831 | ||
| A mathematical model to estimate global hepatitis B disease burden and vaccination impact. | Q51961246 | ||
| Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization | Q57002991 | ||
| A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J | Q24646080 | ||
| Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I". | Q33533304 | ||
| Accumulation of substrates of the anaphase-promoting complex (APC) during human cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the dissociation and relocalization of APC subunits | Q34007645 | ||
| Geographical and genetic diversity of the human hepatitis B virus | Q34098789 | ||
| Comprehensive control (or elimination) of hepatitis B virus transmission in the United States | Q34441991 | ||
| Diagnostic strategy for occult hepatitis B virus infection | Q34757381 | ||
| Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region | Q35033602 | ||
| New immunization initiatives and progress toward the global control of hepatitis B. | Q35103815 | ||
| Legend of hepatitis B vaccination: the Taiwan experience | Q35632769 | ||
| Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy | Q36234130 | ||
| Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes | Q36436398 | ||
| The global impact of vaccination against hepatitis B: a historical overview | Q37291850 | ||
| Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China | Q37495971 | ||
| Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. | Q37591589 | ||
| Epidemiology of hepatitis B and C viruses: a global overview | Q37685594 | ||
| Risks of chronicity following acute hepatitis B virus infection: a review | Q40552593 | ||
| Hepatitis B vaccine: risks and benefits of universal neonatal vaccination | Q40599011 | ||
| Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine. | Q40732329 | ||
| Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. | Q42625588 | ||
| The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations | Q43048511 | ||
| Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection | Q43998254 | ||
| Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis | Q44020464 | ||
| Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. | Q44034326 | ||
| Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. | Q44135004 | ||
| Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees | Q44391370 | ||
| A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China | Q45017879 | ||
| A comparative epidemiological study of hepatitis B and hepatitis D virus infections in Yanomami and Piaroa Amerindians of Amazonas State, Venezuela | Q45187965 | ||
| Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. | Q45364550 | ||
| P433 | issue | 12 | |
| P921 | main subject | hepatitis B | Q6853 |
| Hepatitis B vaccine | Q117749 | ||
| vaccine | Q134808 | ||
| P304 | page(s) | 1709-1715 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity | |
| P478 | volume | 10 |
| Q26765290 | Better plans and more powerful evidence are needed in the research and treatment of chronic hepatitis B in China |
| Q30382346 | Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia |
| Q40047815 | Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. |
| Q39047929 | DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. |
| Q38627568 | Detecting Exact Breakpoints of Deletions with Diversity in Hepatitis B Viral Genomic DNA from Next-Generation Sequencing Data |
| Q53835123 | Determining the Actual Prevalence of Hepatitis B in Khyber Pakhtunkhwa-Pakistan: A Meta-Analysis. |
| Q46620323 | Do we need better hepatitis B vaccines? |
| Q57930358 | Editorial |
| Q40333038 | Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes |
| Q39428108 | HCC-Associated Single Nucleotide Variants and Deletions Identified Using Genome-Wide High Throughput Analysis of HBV. |
| Q89727558 | Hepatitis B surface antibodies seroprevalence among people born before and after implementation of universal HBV vaccination |
| Q37044324 | Hepatitis B viral replication influences the expression of natural killer cell ligands |
| Q39807048 | Hepatitis B virus basal core promoter mutations show lower replication fitness associated with cccDNA acetylation status. |
| Q40707546 | Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine |
| Q37347740 | Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer. |
| Q38252962 | Improving clinical outcomes of chronic hepatitis B virus infection. |
| Q54256788 | Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. |
| Q55405993 | Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. |
| Q33623694 | Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman |
| Q33780105 | Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions |
| Q38098583 | Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides. |
| Q39995705 | Role natural killer group 2D-ligand interactions in hepatitis B infection. |
| Q38675773 | The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience |
| Q42412334 | Unsolved problems and future perspectives of hepatitis B virus vaccination |
| Q35097179 | Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. |
Search more.